Cost Has Many Going Around Doctors to Get Weight-Loss Meds
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Sept. 17, 2024 -- Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days.
They’re in short supply, and often too expensive to afford without insurance coverage.
Because of these barriers, many people are doing an end-run around their doctor’s office, reaching out to potentially unreliable sources that promise to set them up with the drugs, a new survey finds.
About 1 in 4 people surveyed said they would consider using an injectable weight-loss drug without consulting their doctor, Ohio State University researchers report.
Their reasons for skipping the doctor include:
Lower cost (18%)
Not covered by insurance (15%)
Unable to get a prescription from their doctor (9%)
Lack of availability through a pharmacy (6%)
However, unlicensed online pharmacies or dodgy telehealth sites could be risky places to turn to for these drugs, experts said.
“It’s really important for those who want to lose weight to first discuss options with their doctor,” said Dr. Shengyi Mao, an internal medicine specialist with Ohio State.
“It is not one-size-fits-all, and every medication can have risks and side effects,” Mao added in a university news release. “A trusted doctor can go through a patient’s medical history and current medications to assess their particular risks and benefits.”
The U.S. Food and Drug Administration has issued two warnings this year about compounded semaglutide, which has caused dosing errors that resulted in severe nausea, vomiting, hypoglycemia and hospitalizations.
Drug compounding involves combining, mixing or altering drugs to create a medication tailored to the needs of an individual patient. The problem is, compounding a drug can make it tough to accurately calculate the proper dose a person should take.
Some compounders are also using semaglutide salt in their concoctions, which is a different active ingredient than the one used in Wegovy and Ozempic.
The FDA also is investigating reports of counterfeit Ozempic being sold in the United States, researchers noted.
“Obesity is a serious and complex chronic disease and shouldn’t be addressed in a one-size-fits-all approach,” Mao said. “That’s why a comprehensive weight management program is often the best choice because losing weight and keeping it off requires a lifestyle change and lifelong commitment.”
“These weight-loss drugs may be effective for some people, but they can cause serious side effects and the weight may return after they stop taking them,” Mao concluded.
The survey involved 1,006 people polled Aug. 16-18 via web and telephone.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-19 00:00
Read more
- Report Finds Big Disparities in Americans' Well-Being by Region
- Autism Diagnoses Rising Among U.S. Children, Adults
- Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
- ASA: Risk for Postoperative Delirium Increased With Poor and Worsening Sleep
- Mixed Link Seen for Gestational Exposure to Flame-Retardant Chemicals and Childhood Obesity
- 1998 to 2023 Saw Decline in Triplet, Higher-Order Birth Rate
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions